Theragenics (NYSE:TGX) said today it picked up Eckert & Ziegler’s U.S. and Canadian brachytherapy seed business. Financial and other terms of the deal were not disclosed by the companies.
The transaction closed on the end of last year, and included U.S. and Candian customers and the rights to EZB’s AnchorSeed, VariStrand and other seed products, as well as the rights to the SeedLock Needle.
“This transaction continues our long-standing commitment to prostate brachytherapy and the physicians and patients who depend on it. As a leading manufacturer and supplier in this market, our focus has always been on quality and service. Theragenics has a long history of providing physicians with the tools necessary to achieve outstanding results for their patients. We welcome the EZB customers and look forward to working with their programs. This transaction enhances our capabilities and expands our product portfolio for brachytherapy. Our legacy is improving lives and curing cancer. This transaction enhances our mission,” CEO Frank Tarallo said in a prepared statement.
Theragenics said the newly acquired products will be added to the company’s existing portfolio, and it will manufacture the devices at its current facilities in Buford, Ga.
“Theragenics has been recognized as a leader in prostate brachytherapy and has been a valued partner of EZB in the United States. I am confident that Theragenics will continue the outstanding quality and service to which the EZB customers and patients they serve have grown accustomed,”EZB managing director Dr. Edgar Löffler said in a press release.